Condition: Angioimmunoblastic T-Cell Lymphoma Recurrent · Angioimmunoblastic T-Cell Lymphoma Refractory · Sponsor: The Affiliated Hospital of Xuzhou Medical University
Angioimmunoblastic T cell lymphoma (AITL) is a rare and aggressive lymphoma. Some patients relapsed after initial treatment or did not respond to standard treatment (refractory). Subsequent treatment options are limited and the efficacy is not ideal. This study attempts to explore the possibility of improving the efficacy of immunotherapy combined with chemotherapy and epigenetic regulatory drugs.
This description comes directly from the study's public registry record.
Wei Sang Doctor · +86136452076 · sw1981726@126.com
Always discuss trial participation with your own doctor first.
| The Affiliated Hospital of Xuzhou Medical University | Xuzhou, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07058103